Test of everolimus to reduce transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18 years
- You have a kidney transplant
- Your biopsy must show microvascular inflammation with only mild chronic scarring
- Your blood tests must NOT show donor-specific antibodies
- Your biopsy must indicate a “missing self” immune marker
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This study looks at using two anti-rejection medicines (everolimus and a lower dose of a calcineurin inhibitor) after a heart transplant. The goal is to see if this combination is safe and effective for keeping your body from rejecting the new heart, while possibly protecting your kidneys compared to standard treatment.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Hear when a new Kidney Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.